Duane F. Alexander, Barbara M. Alving, James F. Battey , Jeremy M. Berg, Francis S. Collins, Anthony S. Fauci, John I. Gallin, Patricia A. Grady, Richard J. Hodes, Sharon H. Hrynkow, Thomas R. Insel, Jack F. Jones, Stephen I. Katz, Story C. Landis, Ting-Kai Li, Donald A. Lindberg, Elizabeth G. Nabel, John E. Niederhuber, Roderic I. Pettigrew, Griffin P. Rodgers, John Ruffin, Antonio Scarpa, David A. Schwartz, Paul A. Sieving, Stephen E. Straus, Lawrence A. Tabak, Nora D. Volkow
J Clin Invest.
2006;
116(6):1462–1464
doi:10.1172/JCI28894
This article Copyright © 2006, The American Society for Clinical Investigation
Abstract
|
Full text
|
PDF
W
e, the directors of the 27 NIH institutes and centers, wanted to respond to the points made by Andrew Marks in his recent editorial. While we appreciate that the scientific community has concerns, the current initiatives and directions of the NIH have been developed through planning processes that reflect openness and continued constituency input, all aimed at assessing scientific opportunities and addressing public health needs.